Caring for cancer patients in the COVID-19 era

April 16, 2020

In Nature Medicine, the seven comprehensive cancer centres of Cancer Core Europe (CCE), including the Netherlands Cancer Institute and Cancer Research UK Cambridge Centre, have shared how they rapidly reorganised their oncological healthcare systems during the COVID-19 pandemic. In this joint effort, the centres offer guidance to institutions globally by outlining their general consensus measures and organisational strategies adopted to make their operations "pandemic proof".

In the space of just a few weeks, the European cancer centres have had to drastically revise and reorganise their patient care and scientific research due to the coronavirus crisis. For example, treatments have been postponed or adjusted to protect the immune systems of patients with cancer; contact moments have been limited or converted to remote interactions, complete with as many guarantees as possible that this will not affect patient care; and clinical studies have been reassessed to see if they should continue. CCE's seven cancer centres have taken steps to maintain high standards of care despite facing shortages of personal protective equipment, beds, staff and other resources.

"In this situation the centres have not, as they're used to, been able to rely upon the knowledge they've built up over years of thorough research," said Emile Voest, Medical Director of the Netherlands Cancer Institute. 'Our medical staff suddenly find themselves in a parallel universe, where they have to use all their know-how, experience and wisdom to make critical clinical decisions in line with new medical and ethical considerations. That's a drastic change. And why it's essential that other medical institutions can draw upon our experiences and choices so that we all become 'pandemic-proof' in a responsible manner. Not least with an eye to the future."

In Nature Medicine the seven European cancer centres share the choices they have made to adapt to the new COVID-19 world, as well as the considerations and uncertainties they face. Together with other such centres around the world, from now on they will continue to generate and disclose new data in order to make well-founded choices and judgements in the future. 'This will probably be a dynamic and rapidly evolving process,' says Voest. 'We hope that our collective experiences will help guide others.'

"Our medical staff across disciplines (surgery, radiology, pathology, radiation oncology and medical oncology) have been truly amazing at very quickly producing COVID-19-adjusted treatment guidelines," said Prof Carlos Caldas, a member of the senior management at the Cancer Research UK Cambridge Centre, whose clinical cancer services are provided by Cambridge University Hospitals and Royal Papworth Hospital. "We hope that our collective experiences will help guide others and will also reassure cancer patients that we are doing everything we can to avoid compromising their oncological care."

There are several aspects that medical institutions need to take into account to ensure continuity in cancer care:'This crisis is also opening up new learning opportunities,' Voest declares. 'Especially with regard to the trend towards using less invasive treatments where possible, which has been picking up gradually in recent years. But also how we can use technological aids to make healthcare faster and more accessible.'
About Cancer Core Europe

Cancer Core Europe (CCE) is an alliance of seven leading European cancer centres, all of which combine scientific research with patient care. CCE was founded in 2014 to accelerate the development of innovative cancer therapies through close collaboration in translational and clinical research. Its seven member centres collectively treat approximately 350,000 patients annually.

Netherlands Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to